Phase II Study of Pembrolizumab Plus Ramucirumab in Metastatic Gastric or GEJ Adenocarcinoma as Salvage Treatment
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 23 Feb 2022 Status changed from not yet recruiting to recruiting.
- 19 Jan 2021 Planned initiation date changed from 1 Dec 2020 to 1 Mar 2021.
- 24 Nov 2020 New trial record